Evaluation of Warfarin Anticoagulation at University of Gondar Comprehensive Specialized Hospital, North-West Ethiopia

Figures & data

Table 1 Socio-Demographic and Clinical Characteristics of Participants at UoGCSH from June 2016 to June 2018 (n=202)

Patient Characteristics	Frequency (%)
Age
18–30years	65 (32.2)
31–45 years	44 (21.8)
46–60years	58 (28.7)
Above 60years	35 (17.3)
Mean age ± SD	44.33 years ±17.05
Sex
Female	134 (66.3)
Male	68 (33.7)
Residence
Urban	141 (69.8)
Rural	61 (30.2)
Duration of anticoagulation
1–3 month	45 (22.3)
4–12month	95 (47)
>12 month	62 (30.7)
Co morbidities
Congestive heart failure	45 (22.3)
Hypertension	20 (9.9)
Hyperthyroidism	23 (11.4)
Diabetes	18 (8.9)
HIV/AIDS	9 (4.5)
Ischemic heart disease.	4 (2)
Epilepsy	6 (3)
0steomyletis	2 (1)
Others*	8 (4)
Quality of anticoagulation
Good quality (TTR>65%)	59 (29.2)
Poor quality (TTR<65%)	143 (70.8)

Notes: *Asthma 1 (0.5%), chronic pulmonary obstructive disease1 (0.5%), chronic liver disease1 (0.5%), chronic kidney disease1 (0.5%), pneumonia1 (0.5%), rheumatoid heart disease 1 (0.5%), chronic disease 1(0.5%), peripheral arthritis 1 (0.5).

Table 2 Clinical Outcome of Patients on Warfarin in COPD at UoGCSH from June 2016 to June 30th 2018 (N= 202)

Age Classification		Clinical Outcome			Total
		Thromboembolism	Emergency Department Visit	Bleeding
18–30 years		7	2	0	9
31–45 years		3	0	3	6
46–60 years		4	0	4	8
Above 60 years		1	1	2	4
Total		15	3	9	27
Percentage of TTR	≥65% good quality	4	0	2
	<65% poor quality	11	3	7
Sex	Male	6	1	1
	Female	9	2	8

Table 3 Frequency and Number of Concomitant Medications Among Patients on Warfarin COPD at UoGCSH from June 2016 to June 2018 (N=202)

Number of Concomitant Medication		Frequency	Percent
	0	24	11.9
	1	11	5.4
	2	27	13.4
	3	32	15.8
	>4	108	53.5
	Total	202	100.0

Table 4 Predictors of Quality of Anticoagulation Among Patients Treated with Warfarin at UoGCSH from June 2016 to June 2018 (N=202)

Variables	Quality of Anticoagulation		Crude Odds Ratio	P-value 95% CI	Adjusted Odds Ratio	P-value 95% CI
	Poor <65%	Good ≥65%
Patients gender
Female	97	37	0.80 (0.42–1.50)	0.484
Male	46	22	1
Presence of co-morbidity
Yes	73	41	0.46 (0.24–0.87)	0.017*	0.48 (0.24–0.96)	0.037**
No	70	18	1
Residence
Urban	98	43	0.81 (0.41–1.59)	0.541
Rural	45	16	1
Number of medications
0	17	7	1
1	9	2	0.98 (0.37–2.59)	0.964
2	19	8	1.81 (0.37–8.87)	0.463
3	21	11	0.60 (0.38–2.41)	0.924
≥4	77	31	0.77 (0.33–1.78)	0.539
Age of patients
18–30 years	53	12	1
30–45years	29	15	2.30 (0.90–5.89)	0.081*	1.67 (0.62–4.50)	0.310
46–60 years	38	20	1.01 (0.40–2.57)	0.986*	1.01 (0.38–2.67)	0.981
>60 years	23	12	0.99 (0.41–2.40)	0.985*	1.00 (0.40–2.50)	0.998
Presence of potentially interacting medication with warfarin
Yes	60	11	3.15 (1.51–6.58)	0.002*	3.09 (1.45–6.59)	0.003**
No	83	48	1

Notes: *p<0.20. **P<0.05.